BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 6801981)

  • 1. Progestogens and arterial disease--evidence from the Royal College of General Practitioners' study.
    Kay CR
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):762-5. PubMed ID: 6801981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen.
    Wilson ES; Cruickshank J; McMaster M; Weir RJ
    Br J Obstet Gynaecol; 1984 Dec; 91(12):1254-60. PubMed ID: 6440589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study.
    Lipson A; Stoy DB; LaRosa JC; Muesing RA; Cleary PA; Miller VT; Gilbert PR; Stadel B
    Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
    Prasad RN; Liew D; Ratnam SS
    Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF; Crook D; Devenport M; Wynn V
    Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progestogen-only microdose followed by estrogen-progestogen combination, a new approach to oral contraception.
    Russowsky M; Sartoretto JN
    Contraception; 1982 Jul; 26(1):41-9. PubMed ID: 7128133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
    Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
    Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progestogen effects and their relationship to lipoprotein changes. A report from the Oral Contraception Study of the Royal College of General Practitioners.
    Wingrave SJ
    Acta Obstet Gynecol Scand Suppl; 1982; 105():33-6. PubMed ID: 6805242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins.
    Wynn V; Niththyananthan R
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):766-71. PubMed ID: 6801982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral contraceptives and cardiovascular risk. Taking a safe course of action.
    Derman RJ
    Postgrad Med; 1990 Sep; 88(4):119-22. PubMed ID: 2204902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral contraceptive agents.
    Shearman RP
    Med J Aust; 1986 Feb; 144(4):201-5. PubMed ID: 3945219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. World Health Organization Task Force on Oral Contraception.
    Contraception; 1980 May; 21(5):445-59. PubMed ID: 7428356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: differential changes in high-density lipoprotein subclasses.
    Krauss RM; Roy S; Mishell DR; Casagrande J; Pike MC
    Am J Obstet Gynecol; 1983 Feb; 145(4):446-52. PubMed ID: 6401927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives.
    Spellacy WN
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):732-4. PubMed ID: 7039318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
    Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
    Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.